PSEN2
Overview
PSEN2 (Presenilin-2) is a transmembrane protein encoded by the PRESENILIN2 gene located on chromosome 1q42.13. It is a critical component of the γ-secretase (gamma-secretase) complex, a multi-protein enzymatic machinery responsible for intramembranous proteolysis of numerous substrate proteins. PSEN2 shares approximately 67% sequence homology with PSEN1 (Presenilin-1) and serves as the catalytic core component of the γ-secretase complex. Mutations in PSEN2 are associated with early-onset Alzheimer's disease (EOAD), typically presenting before age 60, though mutations generally confer less aggressive disease phenotypes compared to PSEN1 mutations. The protein consists of nine transmembrane domains and localizes primarily to the endoplasmic reticulum and Golgi apparatus, with some distribution to the plasma membrane.
Function/Biology
PSEN2 functions as the catalytic subunit of the γ-secretase complex, working in concert with three other essential components: nicastrin (NCT), anterior pharynx defective-1 (APH1), and presenilin enhancer-2 (PEN2). This complex recognizes substrate proteins that have undergone ectodomain shedding by α-secretase or β-secretase, then cleaves the remaining membrane-anchored C-terminal fragments. The active site of PSEN2 contains two conserved aspartate residues (Asp-257 and Asp-385 in human PSEN2) that are essential for catalytic activity and substrate hydrolysis within the lipid bilayer.
...PSEN2
Overview
PSEN2 (Presenilin-2) is a transmembrane protein encoded by the PRESENILIN2 gene located on chromosome 1q42.13. It is a critical component of the γ-secretase (gamma-secretase) complex, a multi-protein enzymatic machinery responsible for intramembranous proteolysis of numerous substrate proteins. PSEN2 shares approximately 67% sequence homology with PSEN1 (Presenilin-1) and serves as the catalytic core component of the γ-secretase complex. Mutations in PSEN2 are associated with early-onset Alzheimer's disease (EOAD), typically presenting before age 60, though mutations generally confer less aggressive disease phenotypes compared to PSEN1 mutations. The protein consists of nine transmembrane domains and localizes primarily to the endoplasmic reticulum and Golgi apparatus, with some distribution to the plasma membrane.
Function/Biology
PSEN2 functions as the catalytic subunit of the γ-secretase complex, working in concert with three other essential components: nicastrin (NCT), anterior pharynx defective-1 (APH1), and presenilin enhancer-2 (PEN2). This complex recognizes substrate proteins that have undergone ectodomain shedding by α-secretase or β-secretase, then cleaves the remaining membrane-anchored C-terminal fragments. The active site of PSEN2 contains two conserved aspartate residues (Asp-257 and Asp-385 in human PSEN2) that are essential for catalytic activity and substrate hydrolysis within the lipid bilayer.
Beyond its role in Alzheimer's-associated amyloid precursor protein (APP) processing, PSEN2 processes numerous physiologically important substrates. These include Notch family proteins, which are essential for development and cell fate determination; N-cadherin, important for cell-cell adhesion; and ErbB4, involved in neuregulin signaling. This functional pleiotropy means that PSEN2 mutations can have broad cellular consequences beyond amyloid-β production.
Role in Neurodegeneration
In Alzheimer's disease pathogenesis, PSEN2 mutations promote neurodegeneration primarily through altered APP cleavage patterns. Pathogenic PSEN2 variants typically increase the ratio of longer, more aggregation-prone amyloid-β species, particularly amyloid-β42 relative to amyloid-β40. This shift in the amyloid-β profile accelerates amyloid plaque formation, oligomerization, and subsequent neuroinflammation. Over 90 PSEN2 mutations have been identified in familial Alzheimer's disease (fAD) patients, making it the third most common fAD gene after APP and PSEN1.
Unlike PSEN1 mutations, which typically cause severe EOAD with symptom onset in the fourth to fifth decade, PSEN2 mutations generally produce more variable penetrance and later disease onset (typically sixth to seventh decade). Some PSEN2 mutations exhibit incomplete penetrance, meaning not all carriers develop clinical dementia during their lifetime, suggesting potential protective genetic or environmental modifiers.
Molecular Mechanisms
PSEN2 mutations cause neurodegeneration through several interconnected mechanisms. The primary pathogenic mechanism involves altered γ-secretase processivity, leading to increased production of amyloid-β42 at the expense of shorter variants. This occurs through mutations affecting substrate specificity or the positioning of the catalytic aspartates within the enzyme's active site cleft. Some mutations also reduce overall γ-secretase activity toward APP while potentially maintaining activity toward other substrates, creating substrate-selective effects.
Additionally, PSEN2 mutations can impair the complex's assembly and trafficking, reduce protein stability, or alter the protein's conformational state. Mutant PSEN2 may also induce endoplasmic reticulum stress through protein misfolding, activate inflammatory pathways, and promote mitochondrial dysfunction in neurons. Recent evidence suggests certain PSEN2 mutations enhance loss-of-function phenotypes, impairing normal Notch signaling and other critical developmental processes in mature neurons.
Clinical/Research Significance
PSEN2 mutations are clinically significant for genetic counseling and early diagnosis in families with fAD. Genetic screening of PSEN2 in patients with EOAD or family history of dementia can identify carriers years before symptom onset, enabling longitudinal monitoring and potential preventive therapeutic interventions. PSEN2 remains a key target for γ-secretase modulator (GSM) development, a therapeutic strategy aimed at shifting amyloid-β production without completely inhibiting the enzyme's activity toward essential substrates like Notch.
- PSEN1 (Presenilin-1) - primary paralogue and most common fAD gene
- APP (Amyloid Precursor Protein) - primary γ-secretase substrate in Alzheimer's disease
- NICASTRIN - structural component of γ-secretase complex
- APH1 (Anterior Pharynx Defective-1) - γ-secretase complex component
- **